Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity
Jeffrey R. Curtis, Annette H M van der Helm–van Mil, Rachel Knevel et al. · Arthritis Care & Research · 2012
OBJECTIVE: Quantitative assessment of disease activity in rheumatoid arthritis (RA) is important for patient management, and additional objective information may aid rheumatologists in clinical decision making. We validated a recently developed multibiomarker disease activity (MBDA) test relative to clinical disease activity in diverse RA cohorts. METHODS: Serum samples were obtained from the Index for Rheumatoid Arthritis Measurement, Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study, and Leiden Early Arthritis Clinic cohorts. Levels of 12 biomarkers were measured and combined according to a prespecified algorithm to generate the composite MBDA score. The relationship of the MBDA score to clinical disease activity was characterized separately in seropositive and seronegative patients using Pearson's correlations and the area under the receiver operating characteristic curve (AUROC) to discriminate between patients with low and moderate/high disease activity. Associations between changes in MBDA score and clinical responses 6-12 weeks after initiation of anti-tumor necrosis factor or methotrexate treatment were evaluated by the AUROC. RESULTS: The MBDA score was significantly associated with the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) in both seropositive (AUROC 0.77, P < 0.001) and seronegative (AUROC 0.70, P < 0.001) patients. In subgroups based on age, sex, body mass index, and treatment, the MBDA score was associated with the DAS28-CRP (P < 0.05) in all seropositive and most seronegative subgroups. Changes in the MBDA score at 6-12 weeks could discriminate both American College of Rheumatology criteria for 50% improvement responses (P = 0.03) and DAS28-CRP improvement (P = 0.002). Changes in the MBDA score at 2 weeks were also associated with subsequent DAS28-CRP response (P = 0.02). CONCLUSION: Our findings establish the criterion and discriminant validity of a novel multibiomarker test as an objective measure of RA disease activity to aid in the management of RA in patients with this condition.
Cited by 184 works. doi:10.1002/acr.21767 Open-access PDF
Authors
- Jeffrey R. Curtis
- Annette H M van der Helm–van Mil
- Rachel Knevel
- Tom W. J. Huizinga
- Douglas J. Haney
- Yijing Shen
- Saroja Ramanujan
- Guy Cavet
- Michael B Centola
- Lyndal K. Hesterberg
- David Chernoff
- Kerri Ford
- Nancy A. Shadick
- Max I. Hamburger
- Roy Fleischmann
- Edward Clark Keystone
- Michael E. Weinblatt
References
- The Equivalence of Weighted Kappa and the Intraclass Correlation Coefficient as Measures of Reliability
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
- Acute-Phase Proteins and Other Systemic Responses to Inflammation
- Better Bootstrap Confidence Intervals
- A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
- Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score.
- Treating rheumatoid arthritis to target: recommendations of an international task force
- Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial
- Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial